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Abstract
Background: No formulation of exogenous insulin available to date has yet been able to mimic
the physiological nictemeral rhythms of this hormone, and despite all engineering advancements,
the theoretical proposal of developing a mechanical replacement for pancreatic β cell still has not
been reached. Thus, the replacement of β cells through pancreas and pancreatic islet
transplantation are the only concrete alternatives for re-establishing the endogenous insulin
secretion in type 1 diabetic patients. Since only 1 to 1.5% of the pancreatic mass corresponds to
endocrine tissue, pancreatic islets transplantation arises as a natural alternative. Data from the
International Islet Transplant Registry (ITR) from 1983 to December 2000 document a total of 493
transplants performed around the world, with progressively worse rates of post-transplant insulin
independence. In 2000, the "Edmonton Protocol" introduced several modifications to the
transplantation procedure, such as the use of a steroid-free immunosuppression regimen and
transplantation of a mean islet mass of 11,000 islet equivalents per kilogram, which significantly
improved 1-year outcomes. Although the results of a 5-year follow-up in 65 patients demonstrated
improvement in glycemic instability in a significant portion of them, only 7.5% of the patients have
reached insulin independence, indicating the need of further advances in the preservation of the
function of transplanted islet. In addition to the scarcity of organs available for transplantation, islets
transplantation still faces major challenges, specially those related to cell loss during the process of
islet isolation and the losses related to the graft site, apoptosis, allorejection, autoimmunity, and
immunosuppression. The main strategies to optimize islet transplantation aim at improving all these
aspects.
Conclusion: Human islet transplantation should be regarded as an intervention that can decrease
the frequency of severe hypoglycemic episodes and improve glycemic control in selected patient
for whom benefits of 4-5 years duration would be very valuable. Its limitations, however, indicate
that the procedure in its current format is not suitable for all patients with type 1 diabetes.
Introduction
Chronic complications related to Type 1 Diabetes are
closely associated to the onset and maintenance of hyper-
glycemia, as demonstrated by the Diabetes Control and
Complication Trial (DCCT) [1] and its follow-up study
(EDIC) [2]. No formulation of exogenous insulin availa-
ble to date has yet been able to mimic the physiological
nictemeral rhythms of this hormone. Despite all engineer-
ing advancements, the theoretical proposal of developing
a mechanical replacement for pancreatic β cell, which
should carry a glucose sensor attached to an insulin pump
capable of performing real time interpretation of glucose
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variations, as well as allied and sustained automatic cor-
rections with feedback, still has not been reached.
Replacement Therapy
To date, the replacement of β cells through pancreas and
pancreatic islet transplantation are the only concrete alter-
natives for re-establishing the endogenous insulin secre-
tion in type 1 diabetic patients. Both procedures have as a
barrier the major initial obstacle to all transplants: organ
scarcity [3]. The vast majority of pancreas and pancreatic
islet transplantation is performed with deceased-donor
organs: brain death or, more recently, following cardiac
arrest [4]. The search for new sources of cells for implants,
by differentiation of embryonic or somatic cells is still
hindered by ethical and technical problems. Improve-
ments in organ preservation techniques, surgical trans-
plantation techniques, immunosuppression, rejection
diagnosis and management of post-procedure complica-
tions have led to considerable progress in the overall sur-
vival of grafts and patients [5].
Despite the promotion of good glycemic control and the
improvement of the recipient's quality of life, the solitary
pancreas transplant may increase the immediate risk of
death mainly due to the complexity of the surgery. More-
over, the presence of exocrine tissue seems to enhance
immunogenicity and, thereby, promote rejection [5].
Since only 1 to 1.5% of the pancreatic mass corresponds
to endocrine tissue and because the exocrine tissue pro-
duces a strong immune response, the transplantation of
pancreatic islets arises as a natural alternative for re-estab-
lishing endogenous insulin secretion. The first report
dates from 1893: a xenotransplant with fragments from
the pancreas of a lamb [6]. It was only in 1967 that Lacy
was able to revert diabetes in rats with transplantation of
pancreatic islets [7]. Nonetheless, subsequent results of
clinical trials have brought frustrating outcomes.
Data from the International Islet Transplant Registry (ITR)
[8] from 1983 to December 2000 document a total of 493
transplants performed around the world, with progres-
sively worse rates of post-transplant insulin independ-
ence: 66% after 1 month, 40% after 1 year, 22% after 2
years, 11% after 3 years, 6% after 4 years and only 2% after
5 years. However, the quality of the transplants has been
improving throughout the years. Of a total of 237 ITR-reg-
istered transplants performed between 1990 and 1999,
the one-year survival rates for patient and graft (defined as
baseline C-peptide > 0.5 ng/mL) were 96% and 41%,
respectively. However, the proportion of insulin-free
patients at one year was only 11%. The transplantation of
over 6,000 islet-equivalents (IE, the number of islets nor-
malized to an islet of 150 μm of diameter) per kg, less
than 8 hours of cold ischemia time and a immunosup-
pression regimen containing anti-T cell antibodies have
elicited higher rates of insulin independence. Until then,
most islet transplantations were performed simultane-
ously or after a kidney transplant [8], in patients who
therefore presented a very poor metabolic control and
progression of vascular complications.
In 2000, the group at University of Alberta, in Edmonton
[9] published a series of 7 patients submitted to pancreatic
islet transplantation in whom the outcomes were superior
to those obtained so far. Patients were 44 years old on
average (ranging from 29 to 54 years old), with a mean
diabetes duration of 35 years (ranging from 18 to 50
years), and normal kidney function. The inclusion criteria
were: type 1 diabetes for over 5 years, C-peptide < 0.48
mg/mL, poor glycemic control despite intensive insulin
therapy, recurrent severe hypoglycemia with coma or met-
abolic instability, to whom the risks of transplantation
and immunosuppression were considered to be lower
than the risks associated to brittle diabetes. The "Edmon-
ton Protocol", as it is known, introduced several modifi-
cations to the transplantation procedure, and the most
important were: [1] induction with anti-IL2-receptor anti-
bodies; [2] steroid-free immunosuppression regimen with
the use of sirolimus and tacrolimus; [3] transplantation of
islets that were freshly prepared without xenoproteins; [4]
transplantation of a mean islet mass of 11,000 IE/kg. All
recipients required islets from at least two donor pancre-
ases to achieve sustained insulin independence after a
median follow-up of 11.9 months.
In 2005, the same group reported the outcomes of a 5-
year follow-up in 65 patients submitted to islet transplan-
tation. The median duration of insulin independence was
15 months and although the majority of patients (82%)
presented graft survival (C-peptide positivity), only 7.5%
maintained insulin independence after 5 years. The glyc-
emic control evaluation demonstrated that patients who
were back on insulin, but maintained a positive C- pep-
tide benefited from the transplantation, as shown by an
HbA1C of 6.7%, while patients who have lost graft func-
tion presented an HbA1C of 9.0% [10].
These findings can be considered promising, since
improvement in glycemic instability was observed in a
significant portion of patients, but it has reinforced the
question of whether islet transplantation should be aimed
at restoring insulin independence or providing adequate
metabolic control. The GRAGIL2 trial was a phase 1-2
study designed to address this issue: primary and second-
ary endpoints were, respectively, the rate of insulin inde-
pendence and the success rate (defined by a composite
score based upon basal C-peptide, HbA1C, hypoglycemic
events, and exogenous insulin needs). Ten type 1 brittle
diabetic patients experiencing severe hypoglycemia
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received 11,089 ± 505 IE/kg, a maximum of two islet infu-
sions and a immunosuppression regimen similar to the
one employed by the Edmonton Protocol. At 12 months,
insulin independence was observed in 3 of 10 patients
and success in 5 of 10 patients, demonstrating that islet
transplantation failed to promote insulin independence,
but tended to succeed in improving metabolic control
[11].
Another trial which reported similar results was the one
designed to test the reproducibility of the Edmonton Pro-
tocol, organized by the Immune Tolerance Network and
which involved 36 patients in 9 islet transplantation cent-
ers. Only 5 (13.8%) patients sustained insulin independ-
ence after two years, but subjects with partial graft
function had a substantial benefit in the metabolic con-
trol. As anticipated, the achievement of insulin independ-
ence after 1 year was significantly influenced by the
previous experience at each center, suggesting that region-
alization of islet-processing facilities could reduce the var-
iation in outcome and improve efficiency in future trials
[12].
The evaluation of the impact of islet transplantation on
chronic complications is hampered by the uncontrolled
and retrospective nature of most of the studies, but it
seems that restoration of islet function protects against
long-term diabetic complications [13]. Várkonyi et al. fol-
lowed 11 patients with a mean duration of functioning
fetal pancreatic islet graft of 9.5 ± 0.2 years and demon-
strated interruption of progression of all microangio-
pathic complications [14]. Fiorina et al. studied the renal
function of 36 patients submitted to combined kidney
islet transplantation, comparing patients with successful
(fasting C-peptide > 0.5 ng/mL for >1 year) versus unsuc-
cessful islet transplants (fasting C-peptide < 0.5 ng/mL).
The successful group demonstrated improvements in
renal function and better kidney graft survival rates after 7
years of follow-up [15]. In another study, a successful
combined kidney islet transplantation was associated
with improvement of cardiovascular function (ejection
fraction, peak filling rate in end-diastolic volume per sec-
ond, QT dispersion) for up to 3 years of follow-up com-
pared with the group who experienced an early failure of
the islet graft or did not receive an islet graft [16].
Stabilization of diabetic retinopathy after functioning islet
transplantation has been demonstrated in a series of 12
patients followed for up to two years [17] and a recent
study reported an increase in the retinal arterial and
venous blood flow at one year in 10 patients submitted to
islet transplantation suggesting a beneficial effect of the
metabolic control on retinal microcirculation [18]. A pos-
itive effect on neuropathy has also been observed after
functioning islet transplantation, with stabilization or
even improvement of nerve conduction velocities [17,19].
Considering the negative impact of brittle diabetes on the
quality of life (QoL), especially in those patients experi-
encing severe hypoglycemic episodes, QoL analyses is an
important endpoint of clinical trials. While some authors
demonstrated that islet transplantation significantly
reduces fear of hypoglycemia but have little impact on
health-related overall QoL [20], others identified a signif-
icant improvement with the use of a diabetes-specific
questionnaire (DQoL). In this latter study, the most com-
mon reported beneficial effects were glycemic stability
and absence of hypoglycemia resulting in a feeling of
independence not experienced before the transplant [21].
Difficulties Related to Pancreatic Islet Transplantation
In addition to the scarcity of organs available for trans-
plantation, pancreatic islets transplantation still faces
major challenges, specially those related to cell loss during
the process of islet isolation and the losses related to the
graft site, apoptosis, allorejection, immunosuppression,
and autoimmunity. The main strategies to optimize pan-
creatic islet transplantation aim at improving all these
aspects.
Related to the donor and to the process of islet isolation
Even with the use of selection criteria to define the best
pancreas donors and avoid allocation of inadequate
organs for transplant, islets start experiencing damage
before pancreas removal because brain death is related to
the production of pro-inflammatory cytokines like TNF,
IL-1beta and IL-6 which induce cell death and decrease
the quality of the graft [22]. Donor characteristics such as
age, previous medical history, body mass index, cause of
death, use of vasopressive agents, and pancreatic size and
fat content are factors that influence the quality of isolated
islets [23,24].
Donor age seems to be directly linked to the quality of the
isolated islets. In younger donors, under 20 years old, it
can be difficult to isolate and purify islets without pro-
moting islet fragmentation due to over digestion. In
donors over 50 years of age, on the other hand, pancreatic
digestion is facilitated - however, the functional reserve of
the islets may be reduced [23]. Ischemia-reperfusion is an
important mechanism of cellular injury in transplants in
general. Since pancreatic islets require a substantial blood
supply in order to remain viable [25], ischemia causes
great damage to the pancreatic tissue. Different preserva-
tion methods and solutions aim at reducing the deleteri-
ous effects of tissue hypoxia, the main being hypothermia
and intra-pancreatic infusion of UW's (University of Wis-
consin) preservation solution, which contains glucose,
electrolytes, colloid, glutathione, allopurinol, adenosine,
and other metabolic substrates which preserve cellular
integrity. Although UW's solution can preserve the pan-
creas for over 24 hours, the longer the period, the worse
the quality of the graft. More recently, the combined use
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of UW and compounds with high oxygen affinity (two-
layer method) has optimized organ preservation [26].
The isolation of pancreatic islets is comprised of several
steps. After removal of the donor's pancreas, the islets are
maintained in the preservation solution until the begin-
ning of the isolation process. Next, a solution of purified
collagenase is infused in the pancreatic duct and the pan-
creas is cut and placed in a chamber at 98.6°F. There is a
period of shaken with the use of small spheres of metal in
order to promote tissue dissociation through enzymatic
and mechanical digestion. The final separation of the exo-
crine and endocrine tissues is performed by Ficoll density
gradient. The human islet preparations are evaluated
regarding purity, morphologic and functional viability
(insulin secretion) and content of endotoxin. The number
of purified islets is expressed as the number of IE.
The functions of the endocrine pancreas are closely related
to its microarchitecture. Interactions with acinar and mes-
enchymal tissues are essential ever since the embryonic
morphogenesis up to the development of mature secre-
tory cells [27]. The metabolic control depends not only on
the integrity of the islets, but also on the interaction
among beta and non-beta cells within the pancreatic islet,
as well as with surrounding islets [28,29]. Therefore, the
function and viability of pancreatic islets are compro-
mised by the separation of the exocrine tissue which pre-
cedes the cell transplant. The mechanical trauma and the
exposure to collagenase and to pancreatic enzymes frag-
ment islets, damaging especially the non-beta cells located
at the periphery [30]. Additionally, the complex vascular
and neuronal network of the pancreas is destroyed, signif-
icantly modifying the biochemical communication
among cells. Thus, the process of islets isolation results in
pro-inflammatory and oxidative stress states, with loss of
cellular viability and apoptosis [31] which begin soon
after the isolation and are closely associated to the failure
of the islet transplant [32].
Although it confers flexibility to the transplant, islet cul-
ture seems to be related to loss of cellular mass. One of the
key points of the Edmonton Protocol was the transplant
of freshly isolated islets, however, the same group has
recently published a study with human islets placed in
culture before transplantation. Although a reduction in
the amount of cells had been observed, there was an
improvement in islets morphology and viability [33].
Related to the recipient
In pancreas transplantations, an increase in the concentra-
tions of anti-GAD (Glutamic Acid Decarboxylase) and
anti-IA2 (protein tyrosine phosphatase, IA-2) autoanti-
bodies is related to the onset of rejection or graft loss [34].
In islet transplantation, the presence of autoantibodies
also correlates with a worse evolution and could be a key
factor in the chronic failure of the graft [35].
Recipient's characteristics also influence the outcome of
islet transplantation. Eligible candidates should be
between 18 and 65 years of age, have type 1 diabetes for
more than 5 years with undetectable serum concentra-
tions of C-peptide, and present recurrent episodes of
hypoglycemia, usually associated with hypoglycemia una-
wareness, labile diabetes or progressive chronic complica-
tions. In the Immune Tolerance Network. [12], advanced,
non-treatable coronary arterial disease; body mass index >
26 kg/m2; insulin requirements > 0.7 UI/kg; HbA1C >
12%; serum creatinine > 1.5 mg/dL or creatinine clearance
< 80 mL/min/1.73 m2 and albuminuria > 300 mg/24 h,
active infections, severe psychiatric diseases or conditions
that may hinder comprehension and treatment compli-
ance were considered exclusion criteria.
Acute complications are related to the procedure itself -
bleedings, branch portal vein thrombosis after islet infu-
sion, accidental gallbladder puncture and transient
increases of transaminases, while chronic complications
are related to the immunosuppressive regimen and graft
rejection. [10]
The implant site also contributes to islets loss. Although
the subcapsular renal space is the site most commonly
used in animal models because it allows graft recovery,
the liver is the site of choice for islet transplantation in
humans. Access can be obtained through laparotomy or
more commonly, through portal vein cannulation moni-
tored by radioscopy [36]. It is believed that the portal
blood enriched in growth factors, the physiological
actions of insulin and glucagon on hepatic glucose metab-
olism, and the easy access to portal vein would be favora-
ble factors. On the other hand, hypoxic injury to the
presinusoidal hepatocytes after islet embolization and an
inflammatory reaction ultimately leading to islet apopto-
sis might take place [37]. Also, focal hyperinsulinemia
and its correlation with hepatic steatosis [38], the direct
action of immunosuppressants on islets [39] before the
first hepatic pass and difficulties in performing biopsies
during the follow-up would be negative factors to the
short-term survival of the islets at this site. After infusion,
the islets are prone to developing nonspecific inflamma-
tory responses to HLA, with the activation of coagulation
and complement systems. Besides, immediately after
transplantation, islets are dependent upon diffusion of
oxygen and nutrients until revascularization by angiogen-
esis is established, a process that takes 7-10 days. This hos-
tile environment with low oxygen tension, increased
production of oxygen-reactive species and presence of
inflammatory cytokines is plenty of stimuli to short-term
cell death. Thus, in the first few days following transplan-
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tation, even under excellent metabolic control, the grafted
tissue is exposed to unfavorable conditions that may
result in cell death [40]. It is estimated that 50-70% of
islets are destroyed in the immediate post transplant
period [41]. However, after three months, the islets are
surrounded by endothelial tissue, being nourished by a
rich capillary network, as demonstrated in a nonhuman
primate model of allogeneic transplantation [42].
Evaluating β-cell function after islet transplantation is a
difficult task. β-Score is a proposed scoring system deter-
mined from plasma glucose values, HbA1c, daily insulin
requirement and stimulated C-peptide response. This
measurement may be more useful than simply assessing
the presence or absence of insulin independence [43].
Recently, Caumo et al. described a simpler and cheaper
score named Transplant estimated function (TEF), which
takes into account only daily insulin requirement and
HbA1c and that can be normalized to the number of
transplanted islets [44]. Radiological methods to detect
graft damage prior to metabolic impairment have also
been sought. Magnetic resonance imaging monitoring
after transplantation of iron-labeled islets was shown to
be feasible and safe in the clinical practice, but this tech-
nique needs optimization, such as improvements on
image resolution and development of quantification
methods to better correlate the signal with the islet mass
[45].
The lack of specific clinical markers of allograft rejection
poses another challenge, since current methods rely only
on monitoring glucose homoeostasis, which may not be
disturbed during the earliest stages of rejection. Also, the
nature of islet transplantation does not permit a biopsy
approach. Thus, the development of a non-invasive clini-
cal assay for detection of early rejection is a very important
step to allow early intervention to reduce the risk of graft
loss [32].
ABO compatibility and a negative donor-recipient serum
cross-match for T cells are required for islet transplanta-
tion, while HLA antigen matching is not. [46]. The immu-
nosuppressive regimen used in the Edmonton Protocol, a
steroid-free combination therapy including dacluzimab,
sirolimus and tacrolimus has improved transplantation
outcomes. However, tacrolimus has diabetogenic effects
[47] and there are in vitro studies showing a direct delete-
rious effect of sirolimus on human islets, impairing glu-
cose-stimulated insulin secretion. On the other hand,
there are experimental and clinical data indicating that
sirolimus exerts a beneficial role in the early post-trans-
plant inflammatory phenomena and some authors sug-
gest that the effect of sirolimus may vary from helpful to
harmful depending on the circumstances and that tailor-
ing immunosuppression might apply to islet transplanta-
tion with regard to the use or avoidance of this
immunossupressor [48].
Additionally, both tacrolimus and sirolimus are able to
interfere with β cell regeneration [49] and a study with
type 1 diabetic patients who received the immunosup-
pressive drugs used in the Edmonton Protocol demon-
strated that the loss of T-cells associated to this regimen
determined an increase in serum concentrations of IL-7
and IL-15, and the proliferation of CD45RO+ memory T-
cells, enriched in specific autoreactive T-cell clones for
GAD 65, which could contribute to the recurrence of
autoimmunity in these patients [37]. These findings sug-
gest that modifying the immunosuppression regimen of
the Edmonton protocol might have positive effects on
graft survival and function.
Islet transplantation has brought better outcomes and
reached standardization to a certain extent only after the
Edmonton results in 2000, but benefits of islet transplan-
tation still remain to be determined.
Perspectives
Among the main measures necessary to achieve better
long-term results in islet transplantation is the develop-
ment of new immunosuppressive agents and of strategies
to induce immunological tolerance. The increase in the
number of successful islets transplantations also require
the elimination of the need for multiple islet donors per
recipient [46].
Several attempts to increase the viability of transplantable
islets have been proposed, mainly related to improvement
of islet isolation process, to pharmacological interven-
tions and to new immunosuppressive protocols. Many
interventions are being tested to improve islet survival,
such as the use of growth factors [50], glucagon-like pep-
tides (GLP) and GLP-1 analogs [51], oxygen carriers [52],
substances that reduce inflammatory response [53], anti-
coagulants [54], antiapoptotic drugs [55] and antioxidant
compounds [44]. Immunoisolation of transplanted islets
with semi-permeable membranes is an attractive strategy
to preclude the use of immunosuppressive agents, how-
ever, the perfect immunoisolation system has not been
found yet.
Prolonged reversal of diabetes obtained in non-human
immunosuppressed primates transplanted with porcine
pancreatic islets suggests that xenotransplant with pig
islets may be an alternative to circumvent problems of
islet availability for diabetic patients. However, for this
transplant modality to reach clinical applicability, long-
term clinical trials should be performed. Among the
aspects to be specifically examined are overcoming the
immune reaction and carefully evaluating the risk of por-
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cine endogenous retrovirus (PERV) transmission [45].
This last aspect is extremely relevant, considering that
recipients of xenografts might be taking immunosuppres-
sive drugs, which decrease the host resistance, increasing
the possibility of virus (re)activation. In spite of these
safety issues, some researches believe that, in the future, it
will be possible to move forward from pre-clinical studies
into clinical trials of xenotransplantation [46].
One of the major limitations of islet transplantation is the
scarcity of islets. Therefore, strategies to develop islet cells
in vitro have been viewed as an alternative to increase β
cell availability prior to transplantation. Recently pub-
lished data provided convincing evidence that human
embryonic stem cells (hES) are competent to generate glu-
cose-responsive, insulin-secreting cells [56]. However,
besides ethical controversies, safety issues have to be
addressed adequately to ensure that potentially tumori-
genic hES are not transplanted among differentiated islet
cells. The use of multipotent stem cells present within the
adult pancreas or the transdifferentiation of exocrine aci-
nar and/or ductal cells into β cells may circumvent these
drawbacks, but it still faces some obstacles such as uncer-
tainty as to the exact nature of stimuli necessary to pro-
mote complete differentiation and the low yield of the in
vitro differentiation procedure.
In conclusion, human islet transplantation should be
regarded as an intervention that can decrease the fre-
quency of severe hypoglycemic episodes and improve gly-
cemic control in selected patient for whom benefits of 4-
5 years duration would be very valuable. The limitations
that have been realized, however, indicate that the proce-
dure in its current format is not suitable for all patients
with type 1 diabetes [57]. Efforts should be made to
improve outcomes of this treatment modality, still con-
sidered experimental, before it can be designated as "non-
research", as it already happens in Canada.
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